Question 1

What is REGENXBIO?

Accepted Answer

REGENXBIO is a Company.

Question 2

How often does REGENXBIO appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 33 articles.

Question 3

When was REGENXBIO first tracked by Ergen?

Accepted Answer

First tracked on Apr 01, 2026.

Question 4

When was REGENXBIO last mentioned in news?

Accepted Answer

Last active on Jul 03, 2026.

Question 5

What is REGENXBIO's current news sentiment?

Accepted Answer

Aggregate sentiment score: -35 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is REGENXBIO in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving REGENXBIO?

Accepted Answer

REGENXBIO Securities Fraud Lawsuit (Apr 01, 2026, 26 articles).

Question 8

How did the "REGENXBIO Securities Fraud Lawsuit" event impact REGENXBIO?

Accepted Answer

REGENXBIO is the defendant in a class action lawsuit alleging that it made false and misleading statements regarding its gene therapy product candidate RGX-111, leading to investor losses. The lawsuit claims REGENXBIO concealed negative efficacy and safety data, including the discovery of a CNS tumor in a study participant.

Question 9

How did the "European Commission approves Novartis' Itvisma" event impact REGENXBIO?

Accepted Answer

REGENXBIO has an exclusive worldwide license with Novartis for recombinant AAV vectors used in SMA gene replacement therapy, indirectly benefiting from Itvisma's approval.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.